Introduction
============

Given their rapid proliferation and high specificity, phages are extensively used in several applications, including rapid detection of pathogenic bacteria ([@B33]), assessment of water quality and sewage treatment efficiency ([@B10]), and classification and identification of bacterial species ([@B29]). These applications of phages are generally based on the premise that the tail protein can identify receptors on the bacterial surface. Moreover, phage-based disease treatments have attracted recent research attention because of increasing concerns with drug resistance in bacteria ([@B27]; [@B12]; [@B28]). The tail protein of phages is significant for the interaction between bacteriophages and host bacteria, and this interaction is a research topic with considerable potential. [@B36] have shown the application of genetically engineered bacteriophage tail proteins as molecular probes for the sensitive and selective detection of *Salmonella enterica*. [@B26] used the tail protein gp12 of T4 phage *in vivo* in rice to counteract lipopolysaccharide (LPS)-induced inflammation.

Recognition of and connection with host cells are important steps for all phages to infect bacterial cells. In general, phages can only be stably adsorbed onto the host bacterial surface by identifying an exposed structure on the cell surface as the recognition receptor and then injecting their genetic materials into the cytoplasm of the host bacteria ([@B20]; [@B31]). Porins, affinity transporters, and LPS are the most common outer membrane components that act as receptors for tailed phages that infect Gram-negative bacterium ([@B21]; [@B32]). N4 phage is one type of phage that infects the Gram-negative bacterium *Escherichia coli*. The protein gp65, which constitutes a sheath surrounding the tail tube of N4 phage ([@B8]), is adsorbed onto the cell surface by recognition of the outer membrane protein NfrA ([@B16]; [@B17]; [@B25]). [@B25] speculated that direct interaction of NfrA with gp65 is responsible for the initial signaling event leading to N4 DNA and vRNAP injection. *Achromobacter xylosoxidans* A22732 is a Gram-negative bacterium that was isolated from a Chinese patient with pneumonia and is resistant to multiple β-lactam antibiotics, including carbapenems. This dangerous opportunistic pathogen is distributed in the water environment ([@B30]; [@B7]). Previous research identified the N4-like phage phiAxp-3 in hospital wastewater. This phage specifically recognizes and pyrolyzes *A. xylosoxidans* A22732 and therefore has potential for phage therapy. The genome of phiAxp-3 has been fully sequenced and annotated to determine whether there were any potentially "undesirable" genes (e.g., virulent and/or toxic genes) present ([@B22]). The absence of these "undesirable" genes has important safety implications ([@B37]). No toxin, virulence, repressor genes, integrases, recombinases nor any bacterial gene were detected ([@B22]). The genome analyses in previous study provide no evidence of any potentially dangerous transducing ability of this lytic phage, supporting the potential of the phage for biocontrol applications ([@B22]). Experimental results on receptor identification showed that the receptor of phiAxp-3 is LPS ([@B22]). LPS can trigger inflammatory responses in humans and animals. Analysis of the interactions between the tail proteins of phages and the LPS receptor can be used to develop potential drugs for clinical treatment ([@B26]).

In this study, tail sheath protein (TSP) sequences of phiAxp-3 were screened bioinformatically, and a region with the same effect as the full-length TSP of the phage was identified by protein truncation experiments. The characteristics of the truncated protein, including toxicity, were investigated. The results of this study offer theoretical foundations for future applications of the TSP of N4-like phages.

Materials and Methods {#s1}
=====================

Bacterial Strains, Phages, Plasmids, and Media
----------------------------------------------

*Achromobacter xylosoxidans* A22732 and phiAxp-3 were stored in our laboratory and cultured at 37°C. *E. coli* DH5α, *E. coli* BL21 (»DE3) competent cells and protein expression plasmid pET28a were purchased from Beijing BIOMED, Co., Ltd. Luria-Bertani (LB) medium was used for bacterial liquid cultures, and soft-agar medium included an additional 0.7% (wt./vol.) agar.

Cloning of TSP Genes of phiAxp-3
--------------------------------

A 25 μL polymerase chain reaction (PCR) system was established by using phiAxp-3 genomic DNA. **Table [1](#T1){ref-type="table"}** lists the primers used. PCR products were recycled using the QIAquick Gel Extraction Kit. *Nhe*I and *Bam*HI double enzyme digestion was performed on PCR products and carrier plasmids. DNA fragments were ligated overnight at 4°C and the target segments of the TSP gene were cloned into pET28a.

###### 

Relevant information on clones produced and investigated in this work.

  Protein expression   Primer F (NheI)/R (BamHI)                                                       Location (bp)   Additive amount of IPTG (mM/L)
  -------------------- ------------------------------------------------------------------------------- --------------- --------------------------------
  ORF69                CTA[GCTAGC]{.ul}ATGTCCATCGATGATTATCG/ CGC[GGATCC]{.ul}TTATTCCGGCACAGCCGTAGC     1--4188         1.0
  ORF69(595--1395)     CTA[GCTAGC]{.ul}GAGGAAGGATGGGGCTGG/ CGC[GGATCC]{.ul}TTATTCCGGCACAGCCGTAGC       1786--4188      1.0
  ORF69(795--1395)     CTA[GCTAGC]{.ul}GTTGGTTCCAGCCCTGTAA/ CGC[GGATCC]{.ul}TTATTCCGGCACAGCCGTAGC      2386--4188      0.6
  ORF69(995--1395)     CTA[GCTAGC]{.ul}CCGCCTACGGGTGTG/ CGC[GGATCC]{.ul}TTATTCCGGCACAGCCGTAGC          2986--4188      0.6
  ORF69(1195--1395)    CTA[GCTAGC]{.ul}AACCCCATGGATGACAT/ CGC[GGATCC]{.ul}TTATTCCGGCACAGCCGTAGC        3586--4188      0.8
  ORF69(795--1195)     CTA[GCTAGC]{.ul}GTTGGTTCCAGCCCTGTAA/ CGC[GGATCC]{.ul}TTACTCAGGAGGAATCGGTTC      2386--3585      0.8
  ORF69(795--1095)     CTA[GCTAGC]{.ul}GTTGGTTCCAGCCCTGTAA/ CGC[GGATCC]{.ul}TTAGACCAGATGCTTACCCGTCAC   2386--3285      0.4
                                                                                                                       

Underlining indicates endonuclease restriction sites.

Expression and Purification of phiAxp-3 TSP Variants
----------------------------------------------------

pET28a containing cloned TSP genes from phiAxp-3 was transformed into *E. coli* BL21 (»DE3) cells and then cultured in high-salinity liquid LB medium (10 g/L of NaCl) supplemented with 0.1% ampicillin (37°C, 180 rpm). When the OD~600\ nm~ reached 0.8, IPTG solution (**Table [1](#T1){ref-type="table"}**) was added and then cell was cultured overnight (25°C, 100 rpm).

Bacteria were collected by centrifugation and washed three times with by 0.5× phosphate-buffered saline (PBS). After resuspension in 15 mL lysis buffer, the bacteria were treated by 30% ultrasonic power (Sonics VCX750, United States) to break the cells (2 s on/4 s off) for 10 min. Then, 20 μL of RNase and DNase were added at room temperature for 1 h, and then mixture was centrifuged at 10,000 *g*/min for 40 min at 4°C. The supernatant was collected and purified using a His-tagged-protein Purification Kit (Beijing CWBIO Company) by following the manufacturer's instructions. Proteins before and after purification were analyzed by SDS-PAGE. The purified proteins were quantified with a Protein Quantification Kit (Beijing BIOMED Company).

Blockage of Phage Adsorption by Purified TSP Variants
-----------------------------------------------------

Fresh *A. xylosoxidans* A22732 solution (50 μL, OD~600\ nm~ = 3.0) and 150 μg/mL TSP variants solution (50 μL) were mixed at 180 rpm for 10 min at 25°C. Then, 100 μL of 10^3^ plaque-forming units (PFU)/mL phage were added and mixed at 16,000 rpm for 3 min at 4°C. The phage titer in the supernatant (residual PFU) was determined by counting the bacteriophage plaques on *A. xylosoxidans* A22732. Addition of 100 μL 1× PBS (instead of TSP) was used as the negative control, and addition of 100 μL 10^3^ PFU/mL phage was used as the positive control. The phage titer of the positive control was defined as 100% ([@B18]). The titer was determined using tested phage suspension and agar overlay technique ([@B4]). Each index was tested three times.

Lipopolysaccharide Extraction
-----------------------------

Fresh *A. xylosoxidans* A22732 solution grown overnight at 37°C was centrifuged at 8000 *g*/min for 2 min at 4°C, cells were killed with 0.5% phenol, and the mixture was centrifuged again at 39000 rpm. The bacterial pellet was washed three times with distilled water, lyophilized, treated with 90% phenol/water (1:1), and heated to 65°C. *A. xylosoxidans* A22732 LPS was extracted for 15 min according to previously published methods ([@B39]). The extract was cooled to 4°C, centrifuged at 5000 *g*/min for 30 min, and the aqueous phase was collected. Distilled water was added to the remaining phenol phase and the extraction process was repeated. LPS was purified according to the method of [@B35]. DNase (20 μg/mL) and RNase (40 μg/mL) were added to the extraction and tubes were kept at 37°C for 4 h. Proteinase K (100 μg/mL) was added to the tubes at 65°C for 1 h, and then they were heated at 100°C for 10 min. The tubes were centrifuged at 8500 *g*/min for 15 min. Supernatants were transferred to 15-mL centrifuge tubes, and two volumes of acetone were added to the extracts. Samples were stored at 4°C overnight to precipitate LPS. The samples were then centrifuged at 2000 *g*/min for 10 min at 4°C, and the precipitates were resuspended in 1 mL distilled water. Extensive dialysis against double distilled water at 4°C was performed until residual phenol was eliminated. Finally, the purified *A. xylosoxidans* A22732 LPS was lyophilized, weighed, and stored at 4°C.

Enzyme-Linked Immunosorbent Assay (ELISA) Verification of the Interaction Between LPS and phiAxp-3 TSP Variants
---------------------------------------------------------------------------------------------------------------

The interaction between *A. xylosoxidans* A22732 LPS and TSP variants of phiAxp-3 was tested by ELISA ([@B24]). *A. xylosoxidans* LPS was diluted to 100 ng/mL with buffer containing (per L) 1.6 g Na~2~CO~3~ and 2.9 g NaHCO~3~. Then, 100 μL of LPS solution was immobilized on an ELISA plate and incubated at 37°C for 2 h. The mixture was rinsed with PBS-TW2 (PBS solution with 0.05% Tween 20). Bovine serum albumin (BSA) diluted in PBS-TW2 was then added at a final concentration of 0.1% and the mixture was left overnight at 4°C. The wells were then rinsed twice with PBS-TW2. *E. coli* 0111:B4 LPS was used as a negative control. Different concentrations of His-tagged proteins (1 μg/mL -- 0.12207 pg/mL) were added (100 μL/well) and the plates were incubated for 30 min at 37°C. The unrelated protein His-tagged fucosidase (from *Bifidobacterium longum* XY01) was used as a negative control. The plate was washed five times with PBS-TW2. In this step, proteins that could not bind to LPS were removed. HRP-conjugated anti-6× His antibody (diluted 1/1,000 in PBS-TW2) was added (100 μL/well) and incubated for 20 min at 37°C. The plate was washed again with PBS-TW2 and incubated for 10 min at room temperature with 50 μL/well SigmaFast OPD substrate before the reaction was stopped by addition of 50 μL of 3 M H~2~SO~4~. The optical density (OD) was measured at 450 nm, and each index was measured three times.

Effects of Different pH Values and Temperatures on the TSP of phiAxp-3
----------------------------------------------------------------------

To explore the effects of pH on the TSP, HCl/NaOH were added to PBS buffer to adjust the pH between 4 and 10. TSP variants were pretreated for 10 min at different pHs and different temperatures (4--70°C, in a water bath). Then, the phage adsorption blockage assay was performed to examine the functionality of the treated TSP.

*In Vitro* Cell Toxicity of the phiAxp-3 TSP
--------------------------------------------

The toxicity of the TSP of phiAxp-3 (and variants) was tested using normal human liver cells (LO2; American Type Culture Collection). LO2 cells were cultured in high-glucose complete Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 1% penicillin (100 U/mL), and streptomycin (100 mg/mL) at 37°C in 5% a CO~2~ atmosphere. Subculture was performed every 4 days (until the cell fusion rate reached 80%). One hundred μL of protein solution diluted in DPBS was added in the following amounts: 12, 6, 3, 1.5, 0.75, or 0.375 μg. In the control group, 100 μL DPBS were added. The survival rate of LO2 cells was tested using the 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di- phenytetrazoliumromide (MTT) method after 24 h of culture ([@B11]). Each index was measured three times.

Accession Number of Nucleotide Sequence
---------------------------------------

The amino acid sequence of the TSP of phiAxp-3 was obtained from the NCBI database (accession number [ALA45538.1](ALA45538.1)). The accession number of the amino acid sequence of N4 phage gp65 in NCBI is [YP_950543](YP_950543).

Statistical Analyses
--------------------

Nucleotide sequences were compared using DNAMAN software 8.0 (Lynnonon Biosoft, Quebec City, QC, Canada). The mean values of triplicate experimental readings were determined and subjected to ANOVA. The means were separated using Duncan's multiple range test with the aid of SPSS version 19.0 (SPSS, Inc., United States).

Results
=======

Expression and Purification of TSP and Variants of phiAxp-3
-----------------------------------------------------------

The TSP of phiAxp-3 was predicted to be the 69th open reading frame (ORF), a 1395 amino acid protein which shares 54% identity with the amino acid sequence of gp65 of the N4 phage (**Figure [1](#F1){ref-type="fig"}**). To analyze the location(s) of the receptor-binding region of the TSP, *E. coli* BL21(»DE3) cells were transformed with pET28a expression plasmids that expressed His-tagged full-length ORF69, ORF69(595--1395), ORF69(795--1395), ORF69(995--1395), ORF69(1195--1395), ORF69(795--1195), or ORF69(795--1095) (**Figures [2A,B](#F2){ref-type="fig"}**). In this notation, for example, ORF69(595--1395) represents amino acids 595 to 1395 of the phiAxp-3 TSP of ORF69. These proteins were then purified by Ni-affinity chromatography with the expected sizes: 154, 88, 66, 44, 22, 44, and 33 kDa, respectively (**Figure [2C](#F2){ref-type="fig"}**).

![Sequence alignment of the tail proteins (TSP) of phages phiAxp-3 and N4. Identical residues are shaded in black. Gaps (indicated by dotted lines) were introduced into the sequences to maximize the alignment. Numbering is from the N-terminal methionine. Multiple sequence alignment was analyzed and edited with DNAMAN software.](fmicb-09-00450-g001){#F1}

![**(A)** Positions of the fragments of the phiAxp-3 TSP studied in this work. The thick lines represent the fragments construced/tested, and the numbers denote the starting and ending amino acid positions. **(B)** Seven fragments spanning different portions of the TSP were expressed as His~6~-tagged fusion proteins: ORF69(full-length), ORF69(595--1395), ORF69(795--1395), ORF69(995--1395), ORF69(1195--1395), ORF69(795--1195), and ORF69(795--1095). **(C)** SDS-PAGE showing the purified TSP variants with molecular masses ranging from 22 to 154 kDa.](fmicb-09-00450-g002){#F2}

Blockage of phiAxp-3 Adsorption by Purified TSP and Variants
------------------------------------------------------------

We hypothesized that the TSP of phiAxp-3 plays a role in receptor recognition. Therefore, it was necessary to test whether the purified TSP and truncations could inhibit phiAxp-3 binding to the host bacterium. The purified proteins were mixed with fresh *A. xylosoxidans* A22732 solution and the plaquing efficiency of phiAxp-3 was measured. TSP, variants ORF69 (i.e., the full-length protein), ORF69(595--1395), ORF69(795--1395), and ORF69(795--1195) could compete with phage phiAxp-3 for adsorption to the host bacteria, thereby inhibiting phage adsorption (**Figure [3](#F3){ref-type="fig"}**), but the other TSP truncations ORF69(995--1395), ORF69(1195--1395) and ORF69(795--1095), could not (*P* \< 0.05). The adsorption assay demonstrated that TSP functions as a receptor-binding protein, and that residues 795 to 1195 of TSP were sufficient to inhibit phiAxp-3 binding to the receptor *in vitro*.

![Effects of purified TSP and truncations on phiAxp-3 adsorption to the host bacterium *Achromobacter xylosoxidans* A22732. Numerical values represent the mean of three parallel test results and different letters represent significant differences between data (*P* \< 0.05).](fmicb-09-00450-g003){#F3}

Binding of TSP and Variants to *A. xylosoxidans* LPS *in Vitro*
---------------------------------------------------------------

A previous report demonstrated that LPS is the adsorption target (receptor) of phage phiAxp-3 ([@B22]). The specific interaction of LPS purified from *A. xylosoxidans* with purified TSP and its variants was confirmed by ELISA (**Figure [4](#F4){ref-type="fig"}**). ORF69(595--1395) (**Figure [4B](#F4){ref-type="fig"}**), ORF69(795--1395) (**Figure [4C](#F4){ref-type="fig"}**) and ORF69(795--1195) (**Figure [4F](#F4){ref-type="fig"}**), like the ORF69 (**Figure [4A](#F4){ref-type="fig"}**), interacted specifically with *A. xylosoxidans* LPS and the results revealed a direct correlation between the concentration of each of these TSP variants and the OD in the ELISA. The other three proteins, ORF69(995--1395) (**Figure [4D](#F4){ref-type="fig"}**), ORF69(1195--1395) (**Figure [4E](#F4){ref-type="fig"}**) and ORF69(795--1095) (**Figure [4G](#F4){ref-type="fig"}**), did not interact with *A. xylosoxidans* LPS. Therefore, consistent with the results of the phage adsorption assay (**Figure [3](#F3){ref-type="fig"}**), residues 795 to 1195 of the TSP are the key region for binding to the receptor, i.e., *A. xylosoxidans* LPS.

![Enzyme-linked immunosorbent assay assessing *A. xylosoxidans* lipopolysaccharide (LPS) interaction with phiAxp-3 TSP and variants. **(A--G)** Represent the *A. xylosoxidans* LPS interaction with ORF69, ORF69(595--1395), ORF69(795--1395), ORF69(995--1395), ORF69(1195--1395), ORF69(795--1195), ORF69(795--1095), respectively.](fmicb-09-00450-g004){#F4}

Effects of Different pHs and Temperatures on the TSP of phiAxp-3
----------------------------------------------------------------

Stability studies of ORF69 and ORF69(795--1195) were conducted at different pH and temperature values. **Figure [5](#F5){ref-type="fig"}** summarizes the results. The optimum pH for the protein function (i.e., binding to the host bacterium) was 7 (**Figure [5A](#F5){ref-type="fig"}**), and the optimum temperatures were between 4 and 25°C (**Figure [5B](#F5){ref-type="fig"}**). The proteins could not effectively compete with phage to adsorb to host bacteria after treatment in acidic (pH 4) or basic (pH 10) conditions.

![Effects of different pH and temperature pretreatments on the activity of the TSP of phiAxp-3. **(A)** pH group; **(B)** temperature group. Numerical values represent the mean of three parallel test results and different letters represent significant differences between data (*P* \< 0.05).](fmicb-09-00450-g005){#F5}

Safety Testing of TSP on Cell *in Vitro* Cell Cultures
------------------------------------------------------

ORF69 and ORF69(795--1195) were tested on the human immortalized normal hepatocyte cell line LO2 *in vitro* to evaluate their direct toxic effects on cells. Cell viability was assessed by the MTT method. ORF69 was toxic to the cell line when applied with protein doses \>1.5 μg/well in cultures, however, no toxic or antiproliferative effects of ORF69(795--1195) were observed (**Figure [6](#F6){ref-type="fig"}**). This result indicates that the cytotoxic region of the TSP is independent of residues 795 to 1195.

![MTT test on survival rates of LO2 cells treated with ORF69 and ORF69(795--1195).](fmicb-09-00450-g006){#F6}

Discussion
==========

Phage phiAxp-3 was isolated from hospital wastewater and specifically lysed *A. xylosoxidans* A22732. phiAxp-3 is an N4-like phage according to morphological study and genome sequencing. However, this novel phage has a different recognition receptor from N4 phage: N4 phage employs the outer membrane protein NfrA as the recognition receptor, whereas phiAxp-3 uses LPS ([@B22]). Gp65 of N4, encoding the TSP, is thought to be the receptor-binding protein. Using the amino acid sequences of TSP of phage N4 as blast query against NCBI database, there is no recognizable sequence similarity between N4 and other reported N4 like phages. This protein was highly unique, the most similar homology searched was the TSP (encoded by ORF69) of phiAxp-3, although they share only 54% amino acid identity and their binding receptors were totally different (outer membrane protein and LPS, respectively). More than 30 N4-like phages have been reported and sequenced, their most notable feature is the giant RNA polymerase carried in the capsid. The tail proteins (such as tail sheath protein, tail fiber protein, or tail spike protein) responsible for receptor binding showed extensive sequence variability among sequenced N4-like phages. Tail proteins of phages are considered to be a major factor in host specificity. This might be one of the reasons why the hosts of N4-like phages are diverse. A previous study showed that 25 N4-like phage genomes share 14 conserved core genes, which do not contain any phage binding genes ([@B5]), the highly unique binding proteins imply a difference in receptor recognition.

In the present study, recombinant full-length TSP (ORF69) of phiAxp-3 and six variants were co-incubated with the host bacterium. The truncated protein ORF69(795--1195) could directly bind to the host bacteria, with the same function as ORF69 (**Figure [3](#F3){ref-type="fig"}**). ELISA confirmed that ORF69(795--1195) could interact directly with *A. xylosoxidans* A22732 LPS *in vitro* (**Figure [4F](#F4){ref-type="fig"}**). [@B3] demonstrated that the T4 bacteriophage tail fiber adhesin for specific LPS recognition is localized near the C-terminus of the protein. In the present study, the essential sequence of phiAxp-3 TSP for specific LPS recognition was also localized near the C-terminus of ORF69. Short proteins recognizing bacterial cells in a specific manner have major implications for better understanding the molecular recognition of cell surfaces and for bacteria detection ([@B3]).

The characterization of potential therapeutic phages or phage preparations should be undertaken. It is necessary to confirm the stability of the therapeutic phages or phage preparations in different physicochemical conditions ([@B13]). Therefore, in this study, stability studies of ORF69 and ORF69(795--1195) were conducted at different pHs and temperatures. Phages may provide good alternatives to conventional antibiotics, especially for treatment of antibiotic-resistant pathogenic bacteria ([@B23]; [@B9]). [@B38] propounded that the therapeutic phages or phage preparations were non-toxic, and other researchers support this view in a recent report ([@B14]).

Almost all phages recognize receptors through the phage tail ([@B6]). Therefore, the characteristics, especially the safety, of tail proteins of phages must be determined. [@B26] demonstrated that the tail protein gp12 of T4 phage is non-toxic. In the present study, the toxicities of ORF69 of phiAxp-3 and ORF69(795--1195) were evaluated using LO2 cells. The survival rate of LO2 cells decreased as the dose of ORF69 (0.375--12 μg/well in cultures) increased, indicating that ORF69 may be toxic to the cells ([@B1]). However, given the same amount of ORF69(795--1195), the survival rate of LO2 cells was \>90% (**Figure [6](#F6){ref-type="fig"}**), indicating that ORF69(795--1195) is non-toxic in this range (doses: 0.375--12 μg/well in cultures).

In this study, ORF69(795--1195) was shown to interact with *A. xylosoxidans* LPS. Recombinant gp12 (the T4 phage tail adhesin) retains the ability to bind LPS, and gp12 was successfully used in an *in vivo* experiment to counteract LPS-induced inflammation in rice ([@B26]). [@B19] demonstrated that a non-toxic LPS binding peptide was an effective anti-inflammatory peptide for the treatment of acute lung injury. [@B2] demonstrated that a synthetic peptide corresponding to amino acid residues 20 through 44 of the neutrophil-derived 37-kDa cationic antimicrobial protein (CAP37 P20--44) can bind lipid A of LPS, which could be useful in attenuating *in vivo* responses induced during endotoxemia, including sepsis. The emergence of antibiotic-resistant bacteria can cause serious clinical and public health problems ([@B15]). N4-like phages have been used as therapeutic agent in phage therapy against *Pseudomonas aeruginosa* infections and have been shown to be safe and effective ([@B34]). Characterization of the TSP of phage phiAxp-3 might expand our knowledge of using phages as an alternative agent to control multidrug-resistant bacteria. As LPS binding proteins/peptides successfully prevented endotoxin-induced responses *in vivo*, ORF69(795--1195) may be used to develop potential drugs for clinical treatment.

Conclusion
==========

In this study, genes for the TSP of the phiAxp-3 and truncated variants were shown to inhibit phiAxp-3 adsorption onto the host bacterial surface. Experimental results showed no significant difference in residual PFU between the experimental groups \[ORF69(595--1395), ORF69(795--1395), and ORF69(795--1195)\] and the control (ORF69). Similar experimental results were observed in the interaction between the TSP variants and LPS from the host bacterium. Therefore, proteins with similar functions to full-length TSP (ORF69) were screened and the shortest was identified: ORF69(795--1195). The *in vitro* cell toxicity of ORF69 and ORF69(795--1195) was tested; ORF69 was highly toxic, but the ORF69(795--1195) was non-toxic when at dose ranges are 0.375--12 μg. These experimental results can provide references for the application of the TSP of phiAxp-3.
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